Pulmonx Corp. (LUNG)

Pulmonx Corp. experienced a significant stock price decline, with the share price decreasing from $6.20 per share on November 20, 2024, to $1.38 as of November 19, 2025. In Q3 2025, Pulmonx reported a loss of -$0.34 per share, beating estimates, with quarterly revenue of $21.50 million, exceeding expectations. A management transition occurred, with Glen French reappointed as President and CEO, and Derrick Sung appointed COO and CFO. Pulmonx participated in investor conferences in September 2025. Q2 2025 revenue was $23.9 million, with strong international performance but slower U.S. adoption, leading to a revision of the full-year revenue guidance. There have been 27 instances of insider selling and 1 purchase of LUNG stock over the past six months. In Q1 2025, Pulmonx reported worldwide sales of $22.5 million, a 20% increase year-over-year, maintaining its initial full-year revenue guidance.

Pulmonx's products are used in elective procedures, leading to possible seasonal slowing of demand at the beginning and end of the year, as well as during summer months. Increased early detection, demographic trends, and strategic partnerships are expanding the patient base and supporting sustained demand and revenue growth. International markets, particularly China, have shown strong underlying demand, though international performance is expected to moderate in the second half of 2025 with typical seasonality.

Pulmonx Corp. is a commercial-stage medical technology company focused on minimally invasive treatments for severe emphysema, a form of COPD, operating in the Healthcare sector, specifically the Medical Equipment, Supplies & Distribution industry, and the Medical Devices sub-industry. The company's flagship product is the Zephyr® Endobronchial Valve System, an FDA-approved device designed to reduce lung hyperinflation in emphysema patients. Pulmonx also offers the Chartis® Pulmonary Assessment System, a diagnostic tool used to identify patients likely to benefit from the Zephyr® Valve treatment. Additionally, the company provides the StratX® Lung Analysis Platform, a cloud-based quantitative CT analysis service, and the LungTraX™ Platform, a cloud-based quantitative computed tomography analysis service.

Pulmonx has a global presence, with its products commercially available in over 25 countries, including the United States, Europe, the Middle East, Africa, and Asia Pacific. The company is actively pursuing regulatory approvals and partnerships to expand its presence in emerging markets where the prevalence of COPD and emphysema is rising.

Pulmonx's brand reputation, particularly concerning its Zephyr® Valve, is generally strong due to its clinical recognition and regulatory approvals, including FDA breakthrough status and inclusion in emphysema treatment guidance documents. No specific negative events such as product recalls or major safety issues directly impacted Pulmonx's brand reputation in the past year. However, the significant decline in the company's stock price and the recent management transition could indirectly affect investor and market perception.

Pulmonx Corp. has a mixed ownership structure, with approximately 64.26% of the company's stock owned by institutional investors, 6.78% by insiders, and 28.96% by public companies and individual investors. Major institutional owners include Primecap Management Co/ca/, Morgan Stanley, BlackRock, Inc., Vanguard Group Inc, Fmr Llc, Silvercrest Asset Management Group Llc, Deutsche Bank Ag, Jacobs Levy Equity Management Inc., Vestal Point Capital LP, Deerfield Management Company, L.P., State Street Global Advisors, Inc., and DWS Investment Management Americas, Inc.